Pharmacoepidemiological Evaluation in Prostate Cancer—Common Pitfalls and How to Avoid Them

Show full item record



Permalink

http://hdl.handle.net/10138/327148

Citation

Siltari, A.; Auvinen, A.; Murtola, T.J. Pharmacoepidemiological Evaluation in Prostate Cancer—Common Pitfalls and How to Avoid Them. Cancers 2021, 13, 696.

Title: Pharmacoepidemiological Evaluation in Prostate Cancer—Common Pitfalls and How to Avoid Them
Author: Siltari, Aino; Auvinen, Anssi; Murtola, Teemu J.
Publisher: Multidisciplinary Digital Publishing Institute
Date: 2021-02-09
URI: http://hdl.handle.net/10138/327148
Abstract: Pharmacoepidemiologic research provides opportunities to evaluate how commonly used drug groups, such as cholesterol-lowering or antidiabetic drugs, may affect the prostate cancer risk or mortality. This type of research is valuable in estimating real-life drug effects. Nonetheless, pharmacoepidemiological studies are prone to multiple sources of bias that mainly arise from systematic differences between medication users and non-users. If these are not appreciated and properly controlled for, there is a risk of obtaining biased results and reaching erroneous conclusions. Therefore, in order to improve the quality of future research, we describe common biases in pharmacoepidemiological studies, particularly in the context of prostate cancer research. We also list common ways to mitigate these biases and to estimate causality between medication use and cancer outcomes.


Files in this item

Total number of downloads: Loading...

Files Size Format View
cancers-13-00696.pdf 957.8Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record